Freemont Management S.A. Trims Stake in AbbVie Inc. $ABBV

Freemont Management S.A. lowered its position in AbbVie Inc. (NYSE:ABBV) by 88.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,000 shares of the company’s stock after selling 7,600 shares during the quarter. Freemont Management S.A.’s holdings in AbbVie were worth $232,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Evolution Wealth Management Inc. purchased a new position in AbbVie during the second quarter worth about $26,000. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie during the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC bought a new position in shares of AbbVie in the second quarter worth approximately $39,000. Finally, Access Investment Management LLC bought a new position in shares of AbbVie in the second quarter worth approximately $44,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Evercore lowered their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. JPMorgan Chase & Co. increased their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Finally, HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Stock Up 3.0%

Shares of NYSE:ABBV opened at $227.57 on Friday. The stock has a market cap of $402.20 billion, a PE ratio of 96.43, a PEG ratio of 0.77 and a beta of 0.35. The company’s fifty day moving average is $223.45 and its 200 day moving average is $220.35. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales and upbeat execution: AbbVie reported record net sales and raised forward visibility after Q4 results, with analysts (e.g., Cantor Fitzgerald) reiterating bullish views and a $250 target tied to Skyrizi and Rinvoq strength. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: Korean post‑marketing Rinvoq study completed — bolsters real‑world evidence for Rinvoq in immunology, supporting long‑term revenue growth for the immunology franchise. Real‑world data can aid uptake and payer discussions. AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
• Neutral Sentiment: Analyst notes and reports are reframing valuation: recent analyst reports (Argus, other coverage) review AbbVie’s pipeline and valuation after strong results — useful for context but not a consensus catalyst. Analyst Report: AbbVie Inc
• Neutral Sentiment: Pipeline updates (elezanumab phase 2): AbbVie updated a Phase 2 study in acute cervical spinal cord injury — monitor readouts for potential long‑term upside but no immediate revenue impact. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury
• Neutral Sentiment: Small analyst PT trim from Evercore ISI: Evercore trimmed its price target modestly but kept an Outperform rating — suggests confidence in fundamentals despite nearer‑term headwinds. Evercore ISI Cuts AbbVie Inc. (ABBV) PT
• Negative Sentiment: Legal and policy risk: AbbVie sued HHS/CMS after Botox was selected for Medicare drug price negotiation under the Inflation Reduction Act — outcome could materially affect Botox pricing and margins. This litigation creates near‑term uncertainty. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Competitive pressure in immunology: J&J’s heavy Tremfya ad spend is intensifying competition for AbbVie’s Rinvoq and Skyrizi, which could pressure market share and growth trajectories in key indications. J&J’s Tremfya roars 2026 ad spend trailed by AbbVie’s Rinvoq and Skyrizi
• Negative Sentiment: U.S. operational changes and Medicaid concessions: AbbVie is reshaping U.S. operations and making Medicaid concessions to manage pricing headwinds — could weigh on near‑term U.S. margins even as it targets long‑term growth. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.